NIAAA Seeks Study Subjects
Researchers at the National Institute on Aging seek participants with mild cognitive impairment or early stage Alzheimer’s disease. Researchers are investigating a drug called “exendin-4” (exenatide, trade name Byetta). The study will see if the injection of exendin-4 is safe and how it affects brain chemistry and memory in people with mild cognitive impairment or mild Alzheimer’s disease. There is no cost for study-related tests or medications. For more information, call the Office of Patient Recruitment, 1-866-444-2214 (TTY 1-866-411- 1010). Refer to study 10-AG-0423.